

# Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/TF8F14811874EN.html>

Date: January 2020

Pages: 241

Price: US\$ 3,500.00 (Single User License)

ID: TF8F14811874EN

## Abstracts

Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020

### SUMMARY

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 42 molecules. Out of which approximately 41 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 12, 2, 2, 15 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Respiratory, Central Nervous System, Ophthalmology, Cardiovascular, Genetic Disorders,

Hematological Disorders, Infectious Disease, Metabolic Disorders and Women's Health which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Vitiligo, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Asthma, Diffuse Large B-Cell Lymphoma, Graft Versus Host Disease (GVHD), Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL), Psoriasis, Psoriatic Arthritis, Triple-Negative Breast Cancer (TNBC), Anaplastic Large Cell Lymphoma (ALCL), Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Bronchiolitis Obliterans, Chronic Lymphocytic Leukemia (CLL), Dermatitis (Eczema), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hidradenitis Suppurativa, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammation, Lymphoma, Mantle Cell Lymphoma, Multiple Sclerosis, Non-Small Cell Lung Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Relapsed Multiple Myeloma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Thrombocytopenia Myelofibrosis, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Aicardi-Goutieres Syndrome (AGS), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Anterior Uveitis, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Hyperplasia, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Diabetic Macular Edema, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Juvenile Arthritis, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lung Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Myxoid Liposarcoma, Non-Hodgkin Lymphoma, Oligoarticular Idiopathic Juvenile Arthritis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid

Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Skin Cancer, Spondyloarthritis (Spondyloarthropathy), Synovial Sarcoma, Systemic Idiopathic Juvenile Arthritis, Takayasu Arteritis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies  
Involved in Therapeutics Development

AbbVie Inc

Aclaris Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

CJ HealthCare Corp

Concert Pharmaceuticals Inc

Dizal (Jiangsu) Pharmaceutical Co Ltd

Eli Lilly and Co

Galapagos NV

Han Wha Pharma Co Ltd

Hangzhou East China Pharmaceutical Group Co Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

Merck & Co Inc

Nissan Chemical Corp

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Sierra Oncology Inc  
Sincere Pharmaceutical Group  
Theravance Biopharma Inc  
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd  
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles  
ABBV-599 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
abrocitinib - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant  
Products  
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued  
Products  
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product  
Development Milestones  
Featured News & Press Releases  
Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..5), H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1)  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Products under Development by Companies, H1 2020 (Contd..5), H1 2020  
Products under Development by Companies, H1 2020 (Contd..6), H1 2020  
Products under Development by Companies, H1 2020 (Contd..7), H1 2020  
Products under Development by Companies, H1 2020 (Contd..8), H1 2020  
Products under Development by Companies, H1 2020 (Contd..9), H1 2020  
Products under Development by Companies, H1 2020 (Contd..10), H1 2020  
Products under Development by Companies, H1 2020 (Contd..11), H1 2020  
Products under Development by Companies, H1 2020 (Contd..12), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by AbbVie Inc, H1 2020  
Pipeline by Aclaris Therapeutics Inc, H1 2020  
Pipeline by Astellas Pharma Inc, H1 2020  
Pipeline by AstraZeneca Plc, H1 2020  
Pipeline by Bristol-Myers Squibb Co, H1 2020  
Pipeline by CJ HealthCare Corp, H1 2020  
Pipeline by Concert Pharmaceuticals Inc, H1 2020



Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, H1 2020  
Pipeline by Eli Lilly and Co, H1 2020  
Pipeline by Galapagos NV, H1 2020  
Pipeline by Han Wha Pharma Co Ltd, H1 2020  
Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, H1 2020  
Pipeline by Incyte Corp, H1 2020  
Pipeline by Japan Tobacco Inc, H1 2020  
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020  
Pipeline by Merck & Co Inc, H1 2020  
Pipeline by Nissan Chemical Corp, H1 2020  
Pipeline by Pfizer Inc, H1 2020  
Pipeline by Portola Pharmaceuticals Inc, H1 2020  
Pipeline by Sareum Holdings Plc, H1 2020  
Pipeline by Sierra Oncology Inc, H1 2020  
Pipeline by Simcere Pharmaceutical Group, H1 2020  
Pipeline by Theravance Biopharma Inc, H1 2020  
Pipeline by Wuxi Fuxin Pharmaceutical Research and Development Co Ltd, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Dormant Products, H1 2020 (Contd..2), H1 2020  
Discontinued Products, H1 2020  
Discontinued Products, H1 2020 (Contd..1), H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Top 10 Indications, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020

### COMPANIES MENTIONED

AbbVie Inc  
Aclaris Therapeutics Inc  
Astellas Pharma Inc  
AstraZeneca Plc  
Bristol-Myers Squibb Co  
CJ HealthCare Corp  
Concert Pharmaceuticals Inc  
Dizal (Jiangsu) Pharmaceutical Co Ltd  
Eli Lilly and Co  
Galapagos NV  
Han Wha Pharma Co Ltd  
Hangzhou East China Pharmaceutical Group Co Ltd  
Incyte Corp  
Japan Tobacco Inc  
Jiangsu Hengrui Medicine Co Ltd  
Merck & Co Inc  
Nissan Chemical Corp  
Pfizer Inc  
Portola Pharmaceuticals Inc  
Sareum Holdings Plc  
Sierra Oncology Inc  
Sincere Pharmaceutical Group  
Theravance Biopharma Inc  
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd

## I would like to order

Product name: Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/TF8F14811874EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TF8F14811874EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970